On a consolidated basis, Ipca Laboratories recorded a 94% increase in net profit to Rs 161.20 crore in Q4 FY21 from Rs 83.05 crore in Q4 FY20.
Operating income increased 3.81% year over year (year on year) to Rs 1,114.66 crore in the quarter.
The company recorded a forex gain of Rs 13.24 crore in the fourth quarter, compared to a loss of Rs 23.62 crore during the same period last year.
Profit before tax in Q4 FY21 was Rs 192.13 crore, up 71.2% from Rs 112.25 crore in Q4 FY20.
The company recorded an 89% increase in consolidated net profit to Rs 1,141 crore on a 16.6% increase in operating income to Rs 5,419.99 crore in FY21 compared to FY20.
Ipca is a pharmaceutical company with a strong export drive which now represents 52% of the company’s revenues. Ipca is vertically integrated and produces finished dosage forms and active pharmaceutical ingredients.
The script fell 7.98% to end at Rs 2,024.25 on Friday.
Powered by Capital Market – Live News
(This story was not edited by Business Standard staff and is auto-generated from a syndicated feed.)
Business Standard has always strived to provide up-to-date information and commentary on developments that matter to you and have broader political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering has only strengthened our resolve and commitment to these ideals. Even in these difficult times resulting from Covid-19, we remain committed to keeping you informed and updated with credible news, authoritative views and cutting edge commentary on relevant current issues.
However, we have a demand.
As we fight the economic impact of the pandemic, we need your support even more so that we can continue to provide you with higher quality content. Our subscription model has received an encouraging response from many of you who have subscribed to our online content. More subscribing to our online content can only help us achieve the goals of providing you with even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practice the journalism we are committed to.
Support quality journalism and subscribe to Business Standard.